# Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

> **NCT01989780** · PHASE2 · COMPLETED · sponsor: **Japan Breast Cancer Research Group** · enrollment: 160 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab
- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant
- **DRUG:** Goserelin
- **DRUG:** leuprorelin

## Key facts

- **NCT ID:** NCT01989780
- **Lead sponsor:** Japan Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-06
- **Final completion:** 2019-06
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2022-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01989780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01989780, "Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01989780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*